این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Middle East Journal of Cancer، جلد ۱۳، شماره ۳، صفحات ۴۴۹-۴۵۷
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی HER2/neu: A Prognostic Marker for Ovarian Carcinoma
چکیده انگلیسی مقاله Background: Ovarian cancer is the second most prevalent gynecological malignancy. Its prognosis is poor with a five-year survival rate of < 50% with the available therapies. There is a constant need for new biological markers. Therefore, we conducted the present study to evaluate the association between human epidermal growth factor receptor (HER2) neu and the clinicopathological features of epithelial ovarian cancer.Method: A prospective, observational analytic study was conducted at Fauji Foundation Hospital, Rawalpindi between November 2018 and October 2019. It was a cross-sectional study with a quantitative correlational study design.Results: We recruited 90 patients. The mean age of diagnosis was 53 ± 8.022 years; 81.1% (n = 73) had raised pretreatment CA-125 levels with stage III (56.7%, n = 51) and grade III (54.4%, n = 49) at presentation. It was seen that 24.4% (n = 22) of the tumors expressed HER2/neu, 65.6% (n = 59) were negative and 10% (n = 9) were equivocal. 72.2% had platinum sensitive disease. According to HER2/neu status, 20% HER2/neu positive patients had platinum sensitive disease and 3.3% had resistant disease; meanwhile, 47.8% HER2/neu negative patients had platinum sensitive disease and 10% were platinum resistant. HER2/neu expression was significantly associated with grade (P = 0.040) and pretreatment CA-125 levels (P = 0.032) whereas our study failed to show a significant association between stage (P = 0.383) and chemotherapy response (P = 0.055).Conclusion: The current study demonstrated that HER2/neu was positive in 24.4% of the patients, which was significantly associated with grade and pretreatment CA-125 level. However, a longer follow-up is needed for survival analysis and establishment of HER2/neu as a prognostic marker for epithelial ovarian cancer.
کلیدواژه‌های انگلیسی مقاله ErbB receptor, Carcinoma, Ovarian epithelial, Prognosis, Platinum sensitivity
نویسندگان مقاله Sharmin Arif |
Oncology Department, Fauji Foundation Hospital, Rawalpindi, Pakistan

Fauzia Abdus Samad |
Oncology Department, Fauji Foundation Hospital, Rawalpindi, Pakistan

Abdus Samad Syed |
Oncology Department, Fauji Foundation Hospital, Rawalpindi, Pakistan

Anum Khan |
Oncology Department, Fauji Foundation Hospital, Rawalpindi, Pakistan

Asif Riaz |
Oncology Department, Fauji Foundation Hospital, Rawalpindi, Pakistan

Rimsha Zahid |
Oncology Department, Fauji Foundation Hospital, Rawalpindi, Pakistan

نشانی اینترنتی https://mejc.sums.ac.ir/article_48280_c9ecd53cd55fa957bf65d0c1819cded2.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات